Adocia S.A.S., Eli Lilly deal

Late last year, Adocia partnered with Eli Lilly to develop and commercialize a version of Lilly's Humalog insulin lispro that uses Adocia's BioChaperone polymer technology. Adocia said the technology increases a protein's solubility, protects against enzyme degradation and extends the protein's action time. Adocia received $10 million up front and is eligible for up to $156 million in milestones, plus royalties. Eli Lilly will be responsible for development costs. ...